Organovo Holdings Inc., a San Diego developer and manufacturer of human tissues using three-dimensional bioprinting technology, said the company’s stock will begin trading on the highest over-the-counter marketplace, OTCQX.

The 3-year-old company has developed a bioprinter that makes human tissue used by drug developers testing the effects of medications.

Organovo said with the upgraded listing, investors can find current financial disclosure and real time level 2 quotes for the company at

Organovo CEO Keith Murphy said the shift is an important step for the company as it moves to commercialization of its technology and seeks to deliver long-term shareholder value.

At midday Oct. 8, shares of the company, traded under the ticker ONVO, were at $2.03, up a nickel from the prior trading day’s closing price. The stock has ranged from $1.24 to $10.90 over the past 52 weeks.